Teresa A Phillips

US Patent:

7402592, Jul 22, 2008

Filed:

Oct 15, 2004

Appl. No.:

10/711969

Inventors:

Scott R. Breining - Winston-Salem NC, US
Balwinder S. Bhatti - Winston-Salem NC, US
Gregory D. Hawkins - Charlotte NC, US
Lan Miao - Advance NC, US
Anatoly Mazurov - Greensboro NC, US
Teresa Y. Phillips - Greensboro NC, US
Craig H. Miller - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/439
C07D 221/22

US Classification:

514299, 546112

Abstract:

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e. g. , Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

US Patent:

7425561, Sep 16, 2008

Filed:

Jul 18, 2006

Appl. No.:

11/458231

Inventors:

Anatoly A. Mazurov - Greensboro NC, US
Jozef Klucik - Rural Hall NC, US
Lan Miao - Advance NC, US
Angela S. Seamans - Jamestown NC, US
Teresa Youngpeter Phillips - Greensboro NC, US
Jeffrey Daniel Schmitt - Winston-Salem NC, US
Craig Harrison Miller - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/44
C07D 415/00
C07D 413/00
C07D 253/08

US Classification:

514299, 514305, 544133, 544137, 544112, 544183

Abstract:

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a Calkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

US Patent:

7754189, Jul 13, 2010

Filed:

Feb 6, 2008

Appl. No.:

12/026847

Inventors:

Anatoly A. Mazurov - Greenboro NC, US
Jozef Klucik - Rural Hall NC, US
Lan Miao - Advance NC, US
Angela S. Seamans - Jamestown NC, US
Teresa Youngpeter Phillips - Greensboro NC, US
Jeffrey Daniel Schmitt - Winston-Salem NC, US
Craig Harrison Miller - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 49/00
C07D 221/02

US Classification:

424 91, 546112

Abstract:

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds, and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

US Patent:

7897611, Mar 1, 2011

Filed:

Feb 26, 2010

Appl. No.:

12/714014

Inventors:

Balwinder Singh Bhatti - Winston-Salem NC, US
Scott R. Breining - Winston-Salem NC, US
Gregory D. Hawkins - Durham NC, US
Anatoly Mazurov - Greensboro NC, US
Lan Miao - Advance NC, US
Craig Harrison Miller - Winston-Salem NC, US
Teresa Y. Phillips - Greensboro NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/439
C07D 221/22

US Classification:

514299, 546112

Abstract:

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e. g. , Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

US Patent:

7981906, Jul 19, 2011

Filed:

Aug 1, 2008

Appl. No.:

12/184312

Inventors:

Gary Maurice Dull - Lewisville NC, US
Anatoly A. Mazurov - Greensboro NC, US
Teresa Y. Phillips - Greensboro NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/439
C07D 453/02
A61P 25/00
A61P 29/00

US Classification:

514305, 546133

Abstract:

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2. 2. 2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

US Patent:

8084462, Dec 27, 2011

Filed:

Jun 4, 2010

Appl. No.:

12/793773

Inventors:

Anatoly A. Mazurov - Greensboro NC, US
Jozef Klucik - Marietta GA, US
Lan Miao - Advance NC, US
Angela S. Seamans - Jamestown NC, US
Teresa Youngpeter Phillips - Greensboro NC, US
Jeffrey Daniel Schmitt - Asheville NC, US
Craig Harrison Miller - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A01N 43/42
A61K 31/44

US Classification:

514304

Abstract:

The present invention relates to the pharmaceutical compositions incorporating compounds capable of affecting nicotinic acetylcholinergic receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the α7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

US Patent:

8541446, Sep 24, 2013

Filed:

May 26, 2011

Appl. No.:

13/116080

Inventors:

Merouane Bencherif - Winston-Salem NC, US
Lisa Benson - Kernersville NC, US
Gary Maurice Dull - Lewisville NC, US
Nikolai Fedorov - Winston-Salem NC, US
Gregory J. Gatto - Winston-Salem NC, US
Kristen G. Jordan - Clemmons NC, US
Anatoly A. Mazurov - Greensboro NC, US
Lan Miao - Advance NC, US
Julio A. Munoz - Walnut Cove NC, US
Inigo Pfeiffer - Kernersville NC, US
Sondra Pfeiffer - Kernersville NC, US
Teresa Phillips - Greensboro NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/439
C07D 453/02
A61P 25/00
A61P 29/00

US Classification:

514305, 546133

Abstract:

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2. 2. 2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

US Patent:

20040002513, Jan 1, 2004

Filed:

Feb 21, 2003

Appl. No.:

10/372642

Inventors:

Anatoly Mazurov - Greensboro NC, US
Jozef Klucik - Rural Hall NC, US
Lan Miao - Advance NC, US
Angela Seamans - Jamestown NC, US
Teresa Phillips - Greensboro NC, US
Jeffrey Schmitt - Winston-Salem NC, US
Craig Miller - Winston-Salem NC, US

International Classification:

C07D453/04
C07D453/02
A61K031/4745
A61K031/454
A61K031/407

US Classification:

514/305000, 514/412000, 514/323000, 546/135000, 546/199000, 548/453000

Abstract:

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a Calkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the 7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.